There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on eFFECTOR Therapeutics (EFTR – Research Report) and Brainsway (BWAY – Research Report) with bullish sentiments.
eFFECTOR Therapeutics (EFTR)
In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Buy rating on eFFECTOR Therapeutics and a price target of $5.00. The company’s shares closed last Wednesday at $0.71.
According to TipRanks.com, Burns has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for eFFECTOR Therapeutics with a $5.80 average price target, implying a 752.9% upside from current levels. In a report issued on August 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $5.40 price target.
See today’s best-performing stocks on TipRanks >>
Brainsway (BWAY)
In a report released today, Boobalan Pachaiyappan from H.C. Wainwright reiterated a Buy rating on Brainsway, with a price target of $12.00. The company’s shares closed last Wednesday at $3.27.
According to TipRanks.com, Pachaiyappan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Brainsway is a Moderate Buy with an average price target of $8.75, which is a 170.1% upside from current levels. In a report issued on August 10, Northland Securities also maintained a Buy rating on the stock with a $5.50 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EFTR:
